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Radiation therapy achieves its therapeutic effects by inducing apoptosis and non-apoptotic cell death. The aim of this focused review 
is to highlight the aspects of the cell death pathways most relevant to conventional fractionated radiation therapy. I review reports 
on how our current understanding of the molecular mechanisms of cell death may enable us to revise the four radiobiological principles 
(reoxygenation, repair of sublethal damage, redistribution of cells in the cell cycle, and repopulation of surviving cells) for radiation 
treatment with fractionated dose delivery. Apoptosis and non-apoptotic forms of cell death are not represented in the linear qua-
dratic model, which is clinically used to calculate the effects of different total doses, dose per fraction and fraction number on repro-
ductive cell death, a mode of cell death associated with lethal chromosome aberrations. Examples are provided to justify or not a reas-
sessment of the role of apoptosis and non-apoptotic cell death in radiosensitivity, tumor cell proliferation and tumor microenvironment. 
As our understanding of apoptosis developed at the molecular level, so did our understanding of other forms of cell death, particu-
larly autophagy and to a lesser extent, senescence. The linear quadratic model remains a guide for the treatment planner. The thera-
peutic clinical roles of apoptosis and non-apoptotic forms of cell death remain to be defined. Their relative importance will probably 
lie in tumor developmental history related to its type, size and stage. Radiobiological research should focus on the quantitative effects 
of dose and fractionation on the radiation induction of apoptotic and non-apoptotic types of cell death and the interplay among cell 
death pathways. This article is part of a Special Issue entitled “Apoptosis: Four Decades Later”.
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INTRODUCTION
Ionizing radiation has been used clinically for the 
treatment of a wide range of human cancers for more 
than 100 years [1]. Radiotherapy reduces the risk 
of cancer recurrence, promotes tumor control, and 
improves survival [2]. At least 50% of all cancer pa-
tients will receive radiotherapy at some stage during 
the course of their illness. It is currently used to treat 
localized solid tumors, such as cancers of the lung, 
colon/rectum, larynx, thyroid, brain/CNS, breast, 
prostate, or cervix, and can also be used to treat leu-
kemia and lymphoma [2, 3]. The aim of radiotherapy 
is to destroy cancer cells with ionizing radiation while 
limiting the damage to nearby healthy tissue. This 
aim has been facilitated by innovations in technology 
and engineering, followed by the computer revolution 
applied to treatment planning, and the recent develop-
ment of sophisticated irradiation techniques, including 
proton and intensity-modulated radiotherapy [4]. 
Current practice of fractionated radiotherapy, 
where tumors are irradiated multiple times, usually 30, 
with small doses per fraction, usually 1.8–2 Gy, over 
several weeks has its roots in decades of clinical obser-
vations and radiobiological research. Collectively, the 
data indicate that the biologic effects of a given dose 
depend strongly on the details of how this dose is de-
livered over time. Fractionation of the radiation dose 
produces, in most cases, better tumor control while 
reducing the level of normal tissue damage compared 
to a single dose. The underlying interpretation has 
been encapsulated in the four Rs of radiation therapy: 
repair of radiation-induced damage between fractions, 
redistribution of cells in the cell cycle, repopulation 
of the tumor during the treatment period by surviving 
tumor cells and reoxygenation of hypoxic cells [5]. 
A fifth R, radiosensitivity expressing a genetic charac-
teristic of cells, has been proposed as a major factor 
determining radiotherapy individual outcome [6]. 
There are at least eight forms of cell death that may 
account for cell killing both normal and tumor tissues 
[7, 8]. Of those, cell death modalities most relevant 
to this discussion are apoptosis [9], autophagy [10] 
(a history of autophagy reviewed in ref. [11]) and the 
loss of clonogenic survival [12]. Both apoptosis and 
autophagy, and their crosstalk are important in under-
standing clonogenic radiosensitivity in vitro and in vivo 
[13, 17–19]. The loss of clonogenic survival is the form 
of cell death quantified by the clonogenic assay, the 
experimental technique for assessing the fraction 
of cells dying (or more precisely, of cells surviving) [7, 
12]. In the context of radiation biology/oncology cell 
death is equated with any process that leads to the loss 
of the proliferative capacity of the cells. Cells that are 
able to form colonies from a single cell are considered 
to have survived the treatment. The clonogenic in vi-
tro data generally, but not always, agree with tumor 
response in vivo [20–22]. Irradiated cells may also 
die by mitotic catastrophe, senescence and necrosis 
[8]. Mitotic catastrophe might not a bona fide form 
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of cell death, because cells that experience mitotic 
catastrophe eventually die by apoptosis or senesce 
[8, 23]. Senescent cells are considered to be dead 
reproductively and usually not contributing to radiation 
response. There is a renewed interest in stress-in-
duced senescence because of a possible relationship 
between autophagy and senescence in treated tumor 
cells and the involvement of these two death modali-
ties in tumor dormancy and disease recurrence [24] 
(reviewed in ref. [25]). In contrast to off-target effects 
of diffused cytotoxins, radiation-induced “bystander 
death” is an unclassified and poorly understood type 
of cell death, perhaps relevant to risk estimation at low 
radiation dose levels but not effects of typical thera-
peutic dose levels [26]. 
Prior reviews dating back more than two decades 
have addressed the role of apoptosis in determining 
radiation response [13, 14, 27–31]. The purpose of this 
review is present a few examples from currently ac-
tive research with tumors and tumor cells of primarily 
non-hematological origin that justify a reassessment 
of the role of apoptosis and non-apoptotic cell death 
in radiation sensitivity, tumor cell proliferation and 
tumor microenvironment.
RADIATION SURVIVAL CURVES AND 
MECHANISMS OF CELL DEATH
Cell death following irradiation is the stochastic 
effect or “chance effect” which a consequence of the 
random, statistical nature of damage. Thus, the magni-
tude of an effect is independent of dose, but the prob-
ability of an effect increases with dose. This stochastic 
nature of cell killing is easily inferred from the shape 
of survival curves, that is, plots of the logarithm of the 
percentage of surviving (clonogenic) cells as a func-
tion of the dose [12]. The initial portion of survival 
curve in the low (therapeutic) dose range (<3–4 Gy) 
can be conveniently described by the linear-quadratic 
(LQ) formula, which enables radiation biologists and 
treatment planners to calculate cell killing by different 
total doses, size of dose fraction, dose rate and frac-
tion number [32].
Implicit in the LQ formula is the assumption that 
radiation produces two different types of damage: 
non-repairable damage described by the linear com-
ponent (~ dose) and repairable damage described 
by the quadratic component (~ dose2). Non-repairable 
damage is synonymous with intrinsic radiosensitiv-
ity, because the linear component is invariant with 
respect to dose delivery variables, such as dose rate 
or fractionation, but modifiable by genetic back-
ground. Well-known examples of genes involved 
in genetic control of intrinsic radiosensitivity are genes 
involved in cell-cycle progression and DNA repair 
(http://sciencepark.mdanderson.org/ labs/wood/dna).
There have been attempts in the 1990s to correlate 
the incidence of apoptosis with clonogenic cell survival 
and to factor apoptosis in the LQ formula [14, 15, 27–
31]. Several authors proposed that radiation-induced 
apoptosis contributes only to the linear component 
of the LQ formula, that is, to intrinsic radiosensitivity 
of a cell [33–37]. This was primarily based on obser-
vations that dose response curves for both apoptosis 
incidence and non-repairable damage are a linear 
function of the dose and that apoptosis incidence 
is independent of how the dose was distributed in time. 
It has been now recognized that the above-men-
tioned direct correlation between sensitivity to the 
induction of apoptosis and loss of clonogenicity ex-
ists only in a limited number of tissues, including 
thymocytes, spermatogonia, hair-follicle cells, stem 
cells of the small intestine and bone marrow, and tis-
sues in developing embryos as well tumors arising 
from these tissues [35, 36, 38–43]. In contrast, other 
studies with solid tumor models in vitro and in vivo 
generally failed to find an association between sensi-
tivity to apoptosis and sensitivity to therapeutic agents 
including ionizing radiation. For results underlying this 
conclusion in experimental settings, see refs. [13–15, 
27, 28]. Similar results were obtained in clinical set-
tings. The majority of studies found no or negative 
association between high apoptosis incidence and 
survival and/or recurrence in cervical, bladder and 
head and neck patients treated with radiotherapy [44] 
(and references therein). In addition, a retrospective 
study of 2739 colorectal cancer patients treated with 
chemo- and radiotherapy showed no association 
between apoptosis resistance and treatment failure. 
However, high apoptosis in a subset of rectal patients 
correlated less recurrences and/or survival [45] (and 
references therein).
There have been several explanations of experi-
mental and clinical results described above. As pro-
posed by Brown and colleagues [30, 44], the time 
period over which apoptosis occurs following irra-
diation could be different in different cell types. Cells 
such as thymocytes, lymphocytes, lymphoblasts and 
stem cells undergo apoptosis shortly after treatment 
(peaking usually at 3–4 h post-irradiation) and prior 
to the first division after treatment (also termed an “in-
terphase cell death”) [35, 38].In these cells apoptosis 
incidence generally correlates with clonogenic cell 
killing. In contrast, this early apoptosis does not occur 
in epithelial cells and tumors of epithelial or mesenchy-
mal origin. In these cells, apoptosis occurs much later 
and subsequent to mitosis (also termed a “postmitotic 
cell death”) [28–31, 34, 39]. Late apoptosis does not 
correlate with clonogenic cell killing and usually does 
not occur at therapeutic dose levels (<3–4 Gy).
Although the genetic mechanisms of X-ray ac-
tion on cells were far from understood in the early 
days of radiation research, scientists realized that the 
clonogenic assay might not take into account all the 
consequences of irradiation. For example, they noted 
that the number of cells in the colonies produced 
by surviving cells depends on the dose they received: 
the larger dose, the larger proportion of small colo-
nies that frequently include morphologically-altered 
cells such as giant and senescent cells [12, 46–53]. 
Hurwitz and Tolmach [50] and Thompson and Suit 
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[51] investigated the fate of irradiated cells of differ-
ent origins using simple imaging tools available in the 
1960s. By this approach, they were able to record the 
division history of specific, initially single cells; that is, 
whether they divided between observations, produced 
morphologically normal or altered daughter cells, 
or disappeared (following their detaching from the 
substratum). These observations furnished evidence 
that even “killed” cells can carry out a limited number 
of divisions and that the average number of divisions 
of which non-surviving cells are capable before the on-
set of death varies with a dose and cell type. The elimi-
nation of “killed” cells from the colony was attributed 
to lysis of detached and rounded cells. It is now known 
that detachment from a solid substrate is one of early 
morphological features of apoptosis and that apop-
totic cells are typically engulfed by surrounding cells, 
and therefore disappear. The anchorage-dependent 
mode of cell death by apoptosis induced by abnormal 
detachment from the extracellular matrix is termed 
anoikis (from a Greek word meaning “homelessness”) 
[7, 8]. A well-designed study of early and late death 
processes in irradiated cells [15] and real-time imag-
ing studies in the late 1990s using advanced imaging 
technologies have refined and extended results on fate 
of irradiated cells [54–56].
REPOPULATION AND MECHANISMS 
OF CELL DEATH 
Repopulation of tumors, during and after radia-
tion treatment, is considered one of the main reasons 
for the failure of conventional fractionated radiation 
therapy, because tumor cell division between frac-
tions may in part compensate for the cell death pro-
duced by each fraction [57–60]. The cell population 
kinetics have been studied experimentally in several 
animal models as well as be retrospectively by ana-
lyzing clinical data [57, 61–63 (reviewed in ref. [58]). 
It is important to present examples of results from 
these studies in order to place current research in the 
proper context. Denekamp [63] and Withers et al. 
[57] showed that tumor repopulation is not evident 
at the beginning of the treatment and that the process 
becomes clinically apparent 3–5 weeks after the start 
of the treatment. This implies that for treatment times 
shorter than 3–5 weeks tumor proliferation had little 
effect. Following the lag phase, accelerated repopu-
lation takes place; the term “accelerated repopula-
tion” describes more rapid multiplication surviving 
clonogens after irradiation than before [57, 61–64]. 
For treatments longer than 5 weeks, the effect of re-
population is eguivalent to a loss of tumor radiation 
dose of 0.6–1.3 Gy/day [57, 63, 64]. 
Although accepted as a process, the mechanisms 
behind accelerated repopulation and its onset are 
topics still debated in the literature. One of the pos-
sible mechanisms responsible for tumor repopulation 
is accelerated cancer stem cell division [65, 66]. The 
cancer stem cell hypothesis proposed that a subset 
of tumor cells is able to maintain and propagate tumor 
[67–70]. The term “tumor stem cells” was first used 
by Makino in 1959 [67] to describe rare tumor cells 
that are more resistant to chemotherapy than the bulk 
of tumor cells. The current view is that cancer stem 
cells originate either from malignant transformation 
of a normal somatic stem cell or a progenitor (non-
stem) cell [65, 66, 68–70]. The possibility of intercon-
version of tumor stem and non-stem cells and what are 
key factors in influencing this plasticity are a matter 
of debate [66, 69–73]. Mechanisms of accelerated 
repopulation based on the cancer stem cell hypothesis 
have been proposed by Dörr [74] and more recently 
revisited by Marcu et al. [75] and Pajonk et al. [66]. The 
latter study suggested that radiation damage might 
recruit quiescent cancer stem cells into the proliferat-
ing pool [66]. Other likely mechanisms, named by Dörr 
[74] “the three As of repopulation”, include accelera-
tion of stem cell division, abortive division and asym-
metrical loss in stem cell division. Accelerated stem 
cell division implies a treatment-induced shortening 
of the cancer stem cell cycle time. Marcu et al. [75] 
modeled post-irradiation accelerated repopulation 
assuming different cell cycle durations. The authors 
concluded that accelerated cancer stem cell division 
is the least likely mechanism responsible for tumor re-
population because it would require a shortening of the 
cancer stem cell cycle to about 1 h, which is biologi-
cally implausible. The third hypothetical mechanism, 
the loss of asymmetrical division (resulting in two stem 
cells, instead of one stem and one differentiated cell) 
remains untested. 
An alternative mechanism of tumor repopulation 
considers non-stem, senescent tumor cells [24, 25, 
76]. Cellular senescence could be activated as a part 
of an adaptive stress response [24, 76–78]. Recent 
studies demonstrated that the pro-survival function 
of autophagy (protective autophagy) is required for the 
efficient execution of the stress-induced senescence 
program [78–80]. Accordingly, protective autophagy 
helps stressed tumor cell survive in a setting of in-
creased metabolic demands, mitigate damage and 
promote recovery of normal functions; alternatively, 
autophagy helps achieve cellular remodeling asso-
ciated with senescence by degradation of specific 
cellular components [78, 81]. Independent regulation 
of apoptosis and autophagy observed in some cellular 
settings; in this scenario, inhibiting one death pathway 
results in activating expressing the other pathway [11, 
16, 17]. Crosstalk between the two death pathways was 
also reported; under this alternative scenario, apop-
tosis depends on prior autophagy [79, 80]. Gewirtz 
[25] described a model whereby the functional con-
sequences of protective autophagy and senescence 
depend on the nature and quantity of the cellular dam-
age. When the damage is extensive such as following 
a large single dose of radiation (e.g. 20 Gy), autophagy 
and senescence might be insufficient to maintain cells 
in a protective state and the majority of irradiated cells 
die. In contrast, when irradiation is delivered over time, 
such as during fractionated therapy (typically 6 weeks), 
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the cells experience progressive but moderate radia-
tion damage after each fraction (about 2 Gy). There 
are several reports showing that during intra-fraction 
intervals (typically 24 h), cells are not able to repair 
completely DNA damage before the application of the 
next radiation dose induces new DNA damage [13, 15, 
82–84]. In two studies [82, 83], accumulation of DNA 
double strand breaks did not trigger apoptosis in vivo 
and in vitro and diverted a fraction of cells into cell cycle 
exit [82]. The authors hypothesized that a growth arrest 
phenotype may precede senescence [82].
From the standpoint of radiation therapy concerns, 
a limitation of the studies by Řezáčová et al. [82] and 
Rűbe et al. [83] are that the only times points examined 
were during fractionated irradiation (up to 5 d in both 
studies). In contrast, Li et al. [85] studied DNA damage 
over an extended period of up to 21 d post-irradiation; 
the authors showed two distinct phases of DNA dou-
ble-strand break induction, an acute phase peaking 
at 3–5 h during first 24-h post X-irradiation, and a post-
acute phase lasting peaking at 5 d during 1–21 d post 
X-irradiation. In addition, they reported activation 
of both apoptotic and non-apoptotic pathways in sur-
vivors during the second wave of DNA double-strand 
break induction [85]. These results are consistent with 
observations from several laboratories [13–17, 22, 23, 
41, 46, 47, 51–53], collectively termed “lethal sector-
ing” [86], which describes the induction of protective 
and death subroutines in individual survivors. There 
is no direct evidence that the impairment of autophagy 
facilitates escape from senescence and reentry of cells 
to the cell cycle [25]. However, it must be noted that 
the detailed analysis of patterns of growth of irradiated 
experimental tumors led Frindel et al. [62] to suggest 
that a proportion of cells exhibiting a growth arrest phe-
notype “are in a reversible state and can be stimulated 
to re-enter division”. 
An alternative model has been proposed by Meyn 
and colleagues [87]. The authors evaluated single 
dose- and fractionation protocols in experimental 
tumors and showed that compared to a single dose, 
fractionated radiation is a more efficient inducer 
of apoptosis; in fact, a proportion of apoptotic cells 
was directly correlated with the number of fraction and 
inversely correlated with tumor growth rates in each 
radiation protocol. In addition, the authors concluded 
that the balance between apoptotic death and cell divi-
sion of survivors after each dose fraction might result 
in the lag period before the onset of repopulation. 
A provocative study by Huang and colleagues [88] 
provided yet another mechanism of tumor repopula-
tion. They reported that under radiation therapy, dy-
ing cells in the tumor mass support the proliferation 
of other live tumor cells. This work demonstrated that 
the activation of a key player in apoptotic cell death, 
caspase-3, in damaged cells is responsible for synthe-
sis and efflux of prostaglandin E2 .How prostaglandin 
E2 stimulate the growth of tumor cells is controversial, 
because as recently noted both extracellular and in-
tracellular prostaglandin E2 participates in a receptor- 
or Bax-mediated apoptotic death, respectively [89]. 
Connell and Weichselbaum [90] and Lauber et al. [91] 
critically addressed the relevance of work by Huang 
et al. [88] to radiation therapy. Just to highlight one 
point, Huang et al. used one or two large X-ray doses 
(6–12 Gy) in their experiments [88]. These doses are 
in the range of doses only used in specialized radiation 
procedures (for example, proton therapy or stereo-
tactic body radiotherapy) that employ 1–5 fractions 
delivered over a short period, at most 2 weeks [92]. 
Because compensatory repopulation starts 3–4 weeks 
after initiation of radiation therapy, repopulation is not 
a factor in such types of radiation treatment. In ad-
dition, it has been shown that apoptosis-inducing 
drugs (for example, taxanes or PARP-inhibitors) given 
prior to radiation therapy significantly reduce tumor 
growth and volume, compared to radiation therapy 
alone [23, 93, 94], whereas the opposite effect would 
be expected based on the study by Huang et al. [88]. 
MICROENVIRONMENT AND MECHANISMS 
OF CELL DEATH
A solid tumor is a complex system composed 
of a mass of proliferating tumor cells, a blood vessel 
network, lymphatic vessels, and a variety of non-
tumor cells and molecules all of which contribute 
to the local microenvironment. The importance of the 
tumor-specific milieu was recognized more than 
120 years ago by Paget who described the concept 
of “seed and soil” to explain site-specific metastatic 
dissemination [95]; he concluded that “although the 
best work in pathology of cancer is done by those who 
are studying the nature of the seed” (cancer cell), the 
“observations of the properties of the soil” (optimal 
milieu for tumor growth) “may also be useful” [95]. 
It has been recognized for more than 40 years that 
interactions between the tumor cell and components 
of its microenvironment shape and determine the 
malignancy phenotype. However, how this complex 
and intertwined tumor system responds to radiation 
therapy is still poorly understood. 
The underlying differences between the physiol-
ogy of normal and tumor tissues stem from the tumor 
vasculature [96]. Structurally, tumor vessels are often 
dilated and leaky. A heterogeneous zonal variability 
of blood supply within a tumor correlates spatially 
with metabolic activity and oxygen supply [97]. It has 
been recently proposed that the tumor vasculature 
can arise from proliferation of endothelial cells from 
local, pre-existing vessels (angiogenesis) or by colo-
nization of circulating endothelial and other specific 
pro-angiogenic cells, mainly myeloid bone marrow-
derived cells (vasculogenesis) [98]. Which of the two 
mechanisms prevails in radiation therapy is a topic still 
debated in the literature [65, 66, 96–98]. While a more 
comprehensive discussion of mechanisms of tumor 
vascularization in naпve and radiation treated tumors 
is outside the scope of this review, it needs to be men-
tioned that Kozin et al. [99] recently reviewed single-
dose effects (12–50 Gy) on a population of endothelial 
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cells and blood perfusion in preclinical models [99]; 
the authors concluded that a body of experimental evi-
dence supports endothelial cell-based angiogenesis 
rather than an alternative mechanism of vasculogen-
esis proposed by Kioi et al. [98].
One group of investigators proposed that the 
response of tumors to irradiation is affected by the 
sensitivity of tumor endothelial cells [100, 101]. Gar-
cia-Barros et al. reported that the tumor-associated 
endothelial cells undergo massive and rapid ceramide-
mediated apoptosis within few hours after irradiation 
leading to indirect tumor cell death. There is no in-
dependent confirmation of these results, as noted 
by Kozin et al. [99]. Indeed, numerous other studies 
reported negligible radiation effects on vessel struc-
ture and function during a few weeks post-irradiation 
(see Table I in ref. [99] and references therein). Ogawa 
et al. [102] attributed findings of Garcia-Barros et al. 
to unusual tumor-host relationships in the tumor model 
they used in [100, 101]. However, note that because 
of the short experimental time frame, apoptosis of tu-
mor cells that would have occurred at later time points 
cannot be ruled out. As discussed, apoptosis is not 
a major contributor of long-term tumor response post-
irradiation. An obvious alternative mechanism, not 
considered by Garcia-Barros et al. [100, 101], is direct 
tumor cell killing by radiation; this can be assessed 
using the conventional in vivo clonogenic assay.
One of consequences of disorganized architecture 
of tumor vessels is a heterogeneous variation of oxy-
gen within the cell mass ranging from and hypoxic 
(<0.5% to 1.5% O2) to normoxic (>1.5% O2) with me-
dian values much lower than normal. The histological 
studies of human bronchial carcinoma by Thomlinson 
and Gray were among the first to provide a mechanism 
for spatially heterogeneous distribution of oxygen 
concentration in tumors [103]. They postulated that 
because of their rapid growth, tumor cells are progres-
sively pushed away from vessels beyond the effective 
diffusion distance (of about 150 μm) thus become hy-
poxic and eventually necrotic. With minor refinements, 
this basic mechanism has been validated in cancers 
of other organs, including the ovary, esophagus, and 
head and neck [104]. Glucose and nutrient distribu-
tions are thought to follow similar patterns to that 
of oxygen. Consequently, the viable regions of tumor 
are characterized by variability of oxygen and glucose 
content in space. In addition, the efficient efflux of hy-
drogen ions from tumor cells combined with inefficient 
buffering capacity of tumor interstitial fluid generates 
extracellular acidosis.
Hypoxia is detrimental to successful radiation ther-
apy because hypoxic cells are typically 2.5 to 3 times 
radioresistant than normoxic cells (as measured 
by the clonogenic assay) [104]. Hypoxia is detrimental 
to chemotherapy because anticancer drugs might not 
reach the target cells distant from blood vessels [105] 
and because hypoxia up-regulates genes involved 
in multidrug resistance [106]. Finally, hypoxia com-
promises curability by cancer surgery, because the 
low oxygen environment promotes survival of tumor 
cells with a more aggressive phenotype, including 
diminished pro-death mechanisms (for example, 
apoptosis), enhanced pro-survival mechanisms (for 
example, switching aerobic to anaerobic energy 
production or activating protective autophagy and/
or senescence) [104–106]. Finally, hypoxia results 
in a limited response to the presence of cancer cells 
by the immune system. Thus, hypoxia in solid tumors 
has a negative impact on the ability of current cancer 
treatment modalities to control solid tumors. 
Landmark studies in the early 1990s demonstrated 
the operation of a specific oxygen-sensing process 
controlled by hypoxia-inducible factor-1 (HIF-1) 
in tumor cells [107]. As a transcription factor, HIF-1 up-
regulates more than more than 100 genes coding 
proteins essential for glucose and iron metabolism, 
mobility, proliferation, cell survival, immune surveil-
lance, angiogenesis and drug resistance [107]. 
Together, the consequences of HIF-1 are directed 
toward maintaining energy production and survival 
of the tumor in a hostile microenvironment. 
Modulation of radiation-induced death pathways 
by factors associated with the tumor microenvironment 
(hypoxia, energy depletion and acidosis) is far from 
completely understood. Several lines of evidence in-
dicate that apoptosis and autophagy co-exist in tumor 
cells and can be activated as independent pathways, 
but they are also interconnected processes. For ex-
ample, both irradiation and hypoxia up-regulate au-
tophagic death and inhibit apoptotic death. However, 
contributions of these processes to the overall survival 
depend on the relative magnitude of cellular stresses 
as well as the cellular context [108–110]. 
Finally, there is increasing evidence that radio-
therapy leads to significant alterations in the tumor 
microenvironment through the induction of soluble 
signals (including regulatory proteins, growth fac-
tors, cytokines and chemokines) [111, 112].The 
most significant among them are survival-regulatory 
proteins including epidermal growth factor [112], 
pro-inflammatory cytokines [113], fibroblastic growth 
factor [114], transforming growth factors α (TGF-α) 
and β (TGF-β) [79] and trefoil factors 1 (TFF1 and 
3 (TFF3) [115]. Unlike fibroblast growth factor, and 
epithelial growth factors and TGF-α , which are early 
radiation-induced events, activation of TGF-β in tumor 
cells is a biphasic event with the second wave of the 
induction beginning 1 d post-irradiation and persisting 
for up 2–3 d post-irradiation [116]; the late induction 
phase may be associated the irradiation-induced 
oxidative stress [111]. The late extracellular induction 
of TGF-β has a tissue-wide, broad spectrum of cellular 
consequences including growth arrest, differentiation, 
migration, invasion, angiogenesis, evasion of the im-
mune system, and apoptosis [117]. In addition, the 
TGF-β induction in fractionated radiation may lead 
to de novo interactions between microenvironmental 
factors and tumor cells, and between different micro-
environment factors with each dose delivery, thus per-
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petuating its bioactivity during radiation therapy [111]. 
Trefoil factors, TFF1 and TFF3, represent a distinct 
class of tumor suppressor genes, whose downstream 
functions in irradiated cells remain yet to be elucidated. 
However, recent studies shed some light on the nature 
of the cellular and molecular events targeted by TFF 
signaling [118–122]. Together, these results indicate 
that the secreted TFF1 and TFF3 proteins have anti-
apoptotic, anti-inflammatory and, paradoxically, anti-
proliferative effects on the tumor and its microenviron-
ment. Whether and to what degree, the action of TFF 
proteins might counterbalance the effects of growth 
factors and other soluble proteins remains unknown. 
However, clinical relevance of TFF1 and TFF3 to radia-
tion therapy can be established based on two effects. 
First, both genes are activated in a p53-independent 
fashion [123]; p53 is the most frequently mutated gene 
in human cancers [124]. Secondly, both genes display 
the unique coordinate, delayed and persistent expres-
sion pattern in irradiated cells [115, 121, 123]. Thus, 
trefoil factors might exert long-lasting protective ef-
fects on normal tissues outside the radiation treatment 
volume; examples include the salivary gland, heart, 
lung, colon, small intestine and prostate, because 
these normal tissues are unavoidably irradiated in the 
course radiotherapy of head and neck, breast, lung 
and prostate cancers. 
CONCLUDING THOUGHTS
Despite the enormous importance of the discovery 
of molecularly controlled death pathways, the con-
tribution of apoptosis, autophagy and senescence 
to radiation induced cell death as measured long-term 
in solid tumors (by clonogenic assays in vitro and 
in vivo) remains unclear.
One reason might be the frequent use of the 
apoptosis-necrosis paradigm or, more recently, the au-
tophagy-senescence-necrosis paradigm to describe 
total cell killing death following irradiation. As noted 
in this review and previously by others (notably by Steel 
[27], Brown and Attardi [30]) most of such studies as-
sessed radiation apoptotic and non-apoptotic effects 
at an early fixed time after a single large dose (usually 
~10 Gy). Thus, future radiobiological research should 
focus on the quantitative (rather than qualitative) ef-
fects of dose, fractionation and time on the induction 
of apoptotic and non-apoptotic types of cell death. 
At present, the published data are too fragmentary 
even to conclude whether or not there is a dose thresh-
old for the induction of different modes of cell death.
The second observation is the often-imprecise and 
confusing classification of cell death in the literature. For 
example, the term “apoptosis” is frequently misapplied 
in the context of cell death by radiation. The Nomencla-
ture Committee on Cell Death (NCCD) published the 
guidelines in 2008 and 2012 on the use of cell death 
terminology [7, 8], but those are usually not followed 
[125]. The NCCD reports emphasized the importance 
of the biochemical features rather than the common-
place reliance on morphological features. As discussed 
by Bucur et al. [125], the same techniques used to de-
tect apoptosis can also detect necrosis (examples in-
clude microscopic observations of DNA fragmentation, 
TUNEL and Annexin V staining). Popular autophagy 
detection methods that rely on solely the redistribution 
of GFP-LC3 fusion proteins into vesicular structures are 
not considered sufficient for diagnosis [8]. 
Thirdly, because of tumor heterogeneity in a single 
patient and phenotypic variations among patients 
undergoing radiation therapy for the same clini-
cally defined disease, it would be important to assess 
whether and how the different death types within the 
tumor (and among patients) might evolve in the course 
of treatment. Radiation affects multiple facets of tumor 
cell physiology. Consequently, it could be expected 
that different cell death mechanisms are not mutually 
exclusive but rather operate in side-by-side or, con-
versely, overlap albeit to a variable degree and several 
characteristics might be displayed at the same time and 
most likely in a dose-dependent manner. The crosstalk 
between pro-survival and pro-death pathways and the 
activation of yet unknown backup pathways add to the 
complexity of how the cell eventually dies. 
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